Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries [0.03%]
关于中东国家药品外部定价对药品影响的评论回复
Zoltán Kaló,Zoltán Vokó,Kasem S Akhras et al.
Zoltán Kaló et al.
Comment on the implications of external price referencing of pharmaceuticals in Middle East countries [0.03%]
中东国家药品外部参考定价的影響分析
João L Carapinha
João L Carapinha
External Price Referencing (EPR) is frequently used by countries to control pharmaceutical prices but studies to substantiate its use in the Middle East (ME) is lacking. The paper by Kalo et al set-out to fill this lacuna through three obje...
Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis [0.03%]
治疗中至重度斑块状银屑病的secukinumab临床及经济性评述
Ian Ty Wong,Kam Shojania,Jan Dutz et al.
Ian Ty Wong et al.
Secukinumab represents the first IL-17A antagonist among the available biologic therapies approved for moderate-to-severe plaque psoriasis management. Secukinumab demonstrated greater efficacy over placebo, etanercept and ustekinumab in pat...
Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future [0.03%]
波黑塞族共和国老年人用药多重性现状及其对未来的影响
Vanda Marković-Peković,Ranko Škrbić,Aleksandar Petrović et al.
Vanda Marković-Peković et al.
The prescribing of medicines is a fundamental component of care for the elderly; however, there is increasing concern with polypharmacy and its impact on morbidity, mortality and costs. As a result, long-term prescription-medicine use and t...
Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea [0.03%]
在韩国文拉法辛缓释片与沃替西汀治疗抑郁症的成本效益分析
Sang-Eun Choi,Mélanie Brignone,Seong Jin Cho et al.
Sang-Eun Choi et al.
Objective: To assess the cost-effectiveness of vortioxetine versus venlafaxine XR (extended-release) in major depressive disorder (MDD) patients in South Korea. ...
Cost of arthritis: a systematic review of methodologies used for direct costs [0.03%]
类风湿性关节炎的经济负担：直接成本计算方法的系统回顾
T K T Lo,Lynne Parkinson,Michelle Cunich et al.
T K T Lo et al.
A substantial amount of healthcare and costs are attributable to arthritis, which is a very common chronic disease. This paper presents the results of a systematic review of arthritis cost studies published from 2008 to 2013. MEDLINE, Embas...
Life expectancy and health expenditure evolution in Eastern Europe-DiD and DEA analysis [0.03%]
东欧的预期寿命和卫生支出演变：双重差分与数据 enveloping 分析
Mihajlo B Jakovljevic,Mira Vukovic,John Fontanesi
Mihajlo B Jakovljevic
Background: Exploration of long-term health expenditure and longevity trends across three major sub-regions of Eastern Europe since 1989. Methods: ...
Patient-reported outcomes for US oncology labeling: review and discussion of score interpretation and analysis methods [0.03%]
美国肿瘤药物说明书患者报告结局的评分解释及分析方法述评
Alan Shields,Cheryl Coon,Yanni Hao et al.
Alan Shields et al.
This paper describes ways to approach the conceptual and practical challenges associated with interpreting the clinical meaning of scores produced by patient reported outcome (PRO) questionnaires, particularly when used to inform efficacy d...
Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy [0.03%]
一线低甲基化药物治疗失败的高危骨髓增生异常综合征患者后续治疗的成本效益分析
Christopher R Cogle,Jesse D Ortendahl,Tanya Gk Bentley et al.
Christopher R Cogle et al.
Purpose: To evaluate optimal salvage therapy in high-risk myelodysplastic syndromes patients who have failed a first-line hypomethylating agent (HMA) therapy, given that treatment choice is challenging. ...
Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer [0.03%]
阿比特龙作为雄激素性前列腺癌的骨保护剂的成本效益分析研究
Athanasios Dellis,Athanasios Papatsoris
Athanasios Dellis
Fortunately, novel agents are nowadays available for the management of patients with castration-resistant prostate cancer (CRPC). Denosumab is a new bone-protective agent, approved for the prevention and management of skeletal-related event...